Phase 4 N=102 A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia
Cervical Dystonia
Primary: Reduction of Total Tsui Score at 4 Weeks From Baseline — -3.98; -4.77 units on a scale — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=180 Evaluation of Boostrix™10 Years After Previous Booster Vaccination
Acellular Pertussis · Tetanus · Diphtheria
Primary: Number of Seroprotected Subjects Against Diphtheria and Tetanus — 53; 59; 65; 54 Participants
Phase 4 N=871 A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine
Influenza · Vaccination Site Reactions (HT)
Primary: Time to Administer Influenza Vaccine (in Seconds) — 90.0; 182.0; 62.6 seconds
Phase 4 N=228 Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)
Attention Deficit Disorder With Hyperactivity
Primary: Dichotomized Clinical Global Impression-Effectiveness (CGI-E) Scale — 7.0; 5.0; 6.0; 6.0 Units on a scale
Phase 4 N=49 Kidney Damage in Patients With Normal eGFR
Coronary Artery Stenosis
Primary: Impact on the Trajectory of Serum and Urinary NGAL Following the Administration of Non-ionic Low Osmolar Contrast Media. — -14.84; -17.71; -9.98; -2.37 ng/mL
Phase 4 N=924 Clarithromycin Resistant Tailored Therapy
Peptic Ulcer · Helicobacter Pylori Infection
Primary: Helicobacter Pylori Eradication Rate — 75.9; 91.2; 79.1 percentage of participants
Phase 4 N=52 Influence of Escitalopram on Fear Conditioning
Fear Conditioning
Primary: Physiological Reactivity as Measured by Square-root Transformed Skin Conductance Conditioned Response in Early Extinction Trials 1 to 4 — 0.745; 0.853; 0.799; 0.717…
Phase 4 N=112 Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency
Bipolar Disorder · Cocaine Dependence
Primary: Days of Cocaine Use — 1.8; 2.8 days
Phase 4 N=1,137 A Study of LUMIGAN® RC in the Clinical Setting
Glaucoma, Primary Open Angle · Ocular Hypertension
Primary: Percentage of Treatment-Naive Patients With Ocular Hyperemia — 32.2; 39.8; 21.3; 5.9 Percentage of Patients
Phase 4 N=23 Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
Inflammation · Pseudophakia
Primary: Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuities — 51.3; 52 letters
Phase 4 N=66 Prevention of Acute Kidney Injury by Erythropoietin in Thoracic Aorta Surgery With Hypothermic Cardiac Arrest
Dissection of Thoracic Aorta
Primary: Incidence of Acute Kidney Injury Based on RIFLE Criteria
Phase 4 N=322 Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
Overactive Bladder
Primary: Percentage of Patients Continent (PPC) — 34.6; 17.1 Percentage of participants
Phase 4 N=128 Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
Skin Irritation
Primary: Area of Erythema and Elevated Responses of Skin to Product — 91; 68; 33; 42 participants
Phase 4 N=180 ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)
Herpes Zoster · Shingles
Primary: Geometric Mean Fold Rise (GMFR) From Day 1 in Varicella Zoster Virus (VZV) Antibody — 2.8 Ratio
Phase 4 N=114 Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease
Schizophrenia · Schizoaffective Disorder · Psychotic Disorders
Primary: The Difference in the Incidence of Any Adverse Events When Patients Switch Their Antipsychotic From Treatment as Usual (TAU) to Paliperidone ER — 0; 2; 27; 43 Participants